search
Back to results

Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2) (Malbec)

Primary Purpose

Type 2 Diabetes

Status
Terminated
Phase
Phase 4
Locations
Argentina
Study Type
Interventional
Intervention
Insulin Glargine
Insulin Glargine
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

21 Years - 74 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with type 2 diabetes.
  • Patients in treatment with OADs (one or more) for at least 1 year who failed metabolic control (HbA1c > 8% and < 11%).
  • FBG > 130 mg/dl and < 240 mg/dl.
  • BMI < 40 kg/m2 and >25 kg/m2.
  • Ability and willingness to follow a tight anti-diabetic therapy and to perform SMBG controls.

Exclusion Criteria:

  • C peptide < 0.30 nmol/l.
  • Unexplained weight loss of more than 10% of body weight in the last 6 months.
  • Pregnant women or women with the intention of becoming pregnant.
  • Women with childbearing potential who will not use contraceptive protection.
  • Breastfeeding women.
  • Patients using or that have used rapid or ultra-rapid acting insulins; except for those patients that have used rapid or ultra-rapid insulins during intercurrences such as AMI, severe infection or surgery.
  • Renal impairment defined as serum creatinine >1.4 mg/dl in women and >1.5 mg/dl in men.
  • Hepatic impairment defined as GPT or GOT above 2x the normal threshold.
  • Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (non selective beta blockers and systemic corticosteroids).
  • History of drug or alcoholic abuse.
  • Diabetic retinopathy with surgical treatment in the 3 months prior to study entry or which may require surgical treatment within 6 months of study entry.
  • Clinically relevant cardiovascular, gastrointestinal, hepatic, neurological, endocrine, hematological, oncologic or other major systemic disease making implementation of the protocol or interpretation of the study results difficult, at the discretion of the investigator.
  • Evidence of an uncooperative attitude, including poor compliance to any anti- diabetic treatment.
  • Known hypersensitivity to insulin glargine.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Sites / Locations

  • Sanofi-aventis administrative office Argentina

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

A

B

Arm Description

This group must follow a defined algorithm. Only the physicians assigned to this group will know the algorithm.

This is the control group, following the physician's standard practice.

Outcomes

Primary Outcome Measures

Mean difference in HbA1c (efficacy)

Secondary Outcome Measures

Minor, severe and nocturnal Hypoglycaemic events (safety)

Full Information

First Posted
February 22, 2008
Last Updated
June 1, 2010
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT00627471
Brief Title
Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)
Acronym
Malbec
Official Title
A 24 Weeks, Randomized, 2 Arms, Controlled, Multi-centre, National, Open-labeled, Parallel Study in Insulin naïve Patients With Type 2 Diabetes to Compare a Lantus Titration Algorithm vs. Physician's Standard Practice
Study Type
Interventional

2. Study Status

Record Verification Date
June 2010
Overall Recruitment Status
Terminated
Why Stopped
Low recruitment in spite of strategies implemented
Study Start Date
January 2008 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Sanofi

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To compare in terms of HbA1c insulin naive patients with Type 2 Diabetes starting with insulin glargine on an algorithm with insulin naive patients starting with insulin glargine on the physician's standard practice. To compare in terms of FBG insulin naïve patients starting with insulin glargine on an algorithm with insulin naïve patients starting with insulin glargine on the physician's standard practice. To compare the percentage of patients achieving HbA1c< 7% in each treatment group. To compare hypoglycaemic events (minor, severe and nocturnal) between groups. To compare average insulin dose between groups. To compare PRO (patients' reported outcomes) between groups. To compare mean changes in body weight between treatment groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Active Comparator
Arm Description
This group must follow a defined algorithm. Only the physicians assigned to this group will know the algorithm.
Arm Title
B
Arm Type
Active Comparator
Arm Description
This is the control group, following the physician's standard practice.
Intervention Type
Drug
Intervention Name(s)
Insulin Glargine
Intervention Description
For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
Intervention Type
Drug
Intervention Name(s)
Insulin Glargine
Intervention Description
In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician. For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic.
Primary Outcome Measure Information:
Title
Mean difference in HbA1c (efficacy)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Minor, severe and nocturnal Hypoglycaemic events (safety)
Time Frame
from the begining of the treatment up to 5 days after the end of the study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with type 2 diabetes. Patients in treatment with OADs (one or more) for at least 1 year who failed metabolic control (HbA1c > 8% and < 11%). FBG > 130 mg/dl and < 240 mg/dl. BMI < 40 kg/m2 and >25 kg/m2. Ability and willingness to follow a tight anti-diabetic therapy and to perform SMBG controls. Exclusion Criteria: C peptide < 0.30 nmol/l. Unexplained weight loss of more than 10% of body weight in the last 6 months. Pregnant women or women with the intention of becoming pregnant. Women with childbearing potential who will not use contraceptive protection. Breastfeeding women. Patients using or that have used rapid or ultra-rapid acting insulins; except for those patients that have used rapid or ultra-rapid insulins during intercurrences such as AMI, severe infection or surgery. Renal impairment defined as serum creatinine >1.4 mg/dl in women and >1.5 mg/dl in men. Hepatic impairment defined as GPT or GOT above 2x the normal threshold. Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (non selective beta blockers and systemic corticosteroids). History of drug or alcoholic abuse. Diabetic retinopathy with surgical treatment in the 3 months prior to study entry or which may require surgical treatment within 6 months of study entry. Clinically relevant cardiovascular, gastrointestinal, hepatic, neurological, endocrine, hematological, oncologic or other major systemic disease making implementation of the protocol or interpretation of the study results difficult, at the discretion of the investigator. Evidence of an uncooperative attitude, including poor compliance to any anti- diabetic treatment. Known hypersensitivity to insulin glargine. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cristian von Schulz-Hausmann
Organizational Affiliation
Sanofi-aventis administrative office Argentina
Official's Role
Study Director
Facility Information:
Facility Name
Sanofi-aventis administrative office Argentina
City
Buenos Aires
Country
Argentina

12. IPD Sharing Statement

Learn more about this trial

Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)

We'll reach out to this number within 24 hrs